NCT07692334 Pucotenlimab Advanced Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07692334—Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07692334 is a hot trial to watch

Advanced Gastroesophageal Junction Adenocarcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07692334 is notable because it evaluates Pucotenlimab in a Phase 2 design while Objective response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) as their best overall response, as assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by an Independent Radiologic Review Committee (IRC). serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of 28 participants across Not reported shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Objective response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) as their best overall response, as assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by an Independent Radiologic Review Committee (IRC). (From the first dose of study treatment until disease progression, initiation of new anti-cancer therapy, withdrawal from study, death, or up to approximately 24 months.)
• Secondary: Disease control rate (DCR) is defined as the proportion of participants who achieve a confirmed complete response (CR), partial response (PR), or stable disease (SD) as their best overall response according to RECIST version 1.1, as assessed by an Independent Radiologic Review Committee (IRC). (From the first dose of study treatment until disease progression, initiation of new anti-cancer therapy, withdrawal from study, death, or up to approximately 24 months.)
• Secondary: Progression-free survival (PFS) is defined as the time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. (From the first dose of study treatment until documented disease progression, death from any cause, or up to approximately 24 months.)
• Secondary: Overall survival (OS) is defined as the time from the first dose of study treatment until death from any cause. (From the first dose of study treatment until death from any cause or up to approximately 24 months.)
• Secondary: Duration of response (DoR) is defined for participants who achieve a confirmed complete response (CR) or partial response (PR), as the time from the first documented objective response until documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. (From the first documented objective response until disease progression, death, or up to approximately 24 months.)

Benchmark readouts in the surrounding field

• Neoadjuvant tislelizumab plus oxaliplatin and S-1 for locally advanced Siewert type II esophagogastric junction adenocarcinoma: A prospective multicenter phase II study. (Phase 2): pCR = 25.0 %
• Perioperative chemotherapy plus disitamab vedotin (RC48) and toripalimab in HER2-overexpressed locally advanced gastric or gastroesophageal junction cancer (PERISCOPE-02): An open-label, single-arm, phase 2 trial. (Phase 2): Surgical morbidity(Clavien-Dindo II/III) = 8.0 %
• Long-term survival results of perioperative chemoimmunotherapy with DCF and avelumab in locally advanced gastro-esophageal adenocarcinoma. (Phase 2): DFS(5-year) = 100.0 % ; DFS(5-year) = 55.3 %

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Pucotenlimab (Approved; PD-1); Becotatug vedotin (Approved; EGFR x Tubulin)

Company & Deal Intelligence context: West China Second University Hospital — China

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07692334 is a focused lens on Advanced Gastroesophageal Junction Adenocarcinoma development. Its value will be determined by whether Pucotenlimab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.